英国初级保健中他汀相关药物不良反应咨询与心血管事件及全因死亡风险:回顾性队列研究
该回顾性队列研究基于英国初级保健数据库,纳入2004至2019年间1 564 687例他汀使用者,其中19 035例(1.22%)发生他汀相关药物不良反应咨询。经倾向评分匹配后,他汀相关不良反应咨询与后续心血管事件风险升高相关(一级预防调整HR 1.39,95%CI 1.23-1.57;二级预防调整HR 1.34,95%CI 1.25-1.42)。发生不良反应后继续他汀或联合其他降脂治疗、或仅用其他降脂治疗,相比停用所有降脂治疗,与更低的心血管事件和全因死亡风险相关。
要点
- 他汀相关不良反应咨询患者后续心血管事件风险显著升高,需加强监测。
- 发生不良反应后继续降脂治疗(他汀或联合其他降脂药)可降低心血管事件和死亡风险。
- 中断所有降脂治疗与更高的心血管事件及全因死亡风险相关。
核心结论
- 他汀相关药物不良反应咨询与后续心血管事件风险增加相关,提示此类患者应更密切监测。
- 继续降脂治疗对预防心血管事件和死亡具有重要性。
研究设计与样本
- 回顾性队列研究,使用IQVIA医学研究数据(原THIN数据库),纳入2004至2019年间1 564 687例他汀使用者。
- 发生他汀相关不良反应咨询的患者按倾向评分1:1匹配至无不良反应咨询的他汀使用者,匹配因素包括人口学、合并症和合并用药。
- 采用Cox比例风险回归比较后续心血管事件和全因死亡风险,按心血管病史分层。
- 二次分析中,在发生他汀相关不良反应的患者中考察1年内治疗变化,并比较不同治疗组的结局。
主要发现
- 19 035例(1.22%)他汀使用者发生他汀相关不良反应咨询。
- 心血管一级预防队列平均随访6.32(标准差3.74)年,二级预防队列平均随访5.31(标准差3.83)年。
- 他汀相关不良反应咨询与后续心血管事件相关:一级预防调整HR 1.39(95%CI 1.23-1.57),二级预防调整HR 1.34(95%CI 1.25-1.42)。
- 在发生不良反应的患者中,与停用所有降脂治疗相比,继续他汀处方或任何他汀联合额外降脂治疗与心血管事件风险降低相关(调整HR 0.71,95%CI 0.64-0.78),全因死亡风险降低(调整HR 0.46,95%CI 0.42-0.50)。
- 仅使用其他降脂治疗也与心血管事件风险降低(调整HR 0.75,95%CI 0.62-0.92)和全因死亡风险降低(调整HR 0.52,95%CI 0.43-0.64)相关。
临床怎么用
- 对发生他汀相关不良反应咨询的患者,应加强心血管事件监测和随访。
- 发生他汀相关不良反应后,应优先考虑继续他汀治疗或换用/联合其他降脂治疗,而非停用所有降脂药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate the risk of cardiovascular disease (CVD) events and all-cause mortality in patients with statin-related adverse drug reaction (ADR) consultation in primary care and examine whether different treatments following the ADR affect subsequent outcomes. METHODS: This was a retrospective cohort study of statin users between 2004 and 2019 using IQVIA Medical Research Data (formally known as the THIN database). Patients with statin-related ADR consultation were matched by propensity score (1:1) to statin users without ADR consultation based on demographics, comorbidities and concomitant medication. Cox proportional hazard regression was used to compare the risk of subsequent CVD event and all-cause mortality, stratified by history of CVD. In the secondary analysis among patients with statin-related ADR, treatment changes within a 1-year period following the ADR were examined and the outcomes were compared between different treatment groups. RESULTS: Among 1 564 687 statin users, 19 035 (1.22%) had a statin-related ADR consultation in primary care. The mean (standard deviation) follow-up time was 6.32 (3.74) years and 5.31 (3.83) years for CVD primary and secondary prevention cohorts, respectively. Statin-related ADR consultation was associated with subsequent CVD events in both cohorts (adjusted hazard ratio [HR] of 1.39 [95% CI 1.23, 1.57] and 1.34 [95% CI 1.25,1.42], respectively). In the secondary analysis among patients with statin-related ADR consultation, we found that (i) continued statin prescription or combination of any statin with additional lipid-lowering treatment (LLT) and (ii) other LLT only were associated with lower risks of CVD event (adjusted HR 0.71 [95% CI 0.64, 0.78] and 0.75 [95% CI 0.62, 0.92], respectively) and all-cause mortality (adjusted HR 0.46 [95% CI 0.42, 0.50] and 0.52 [95% CI, 0.43, 0.64], respectively), compared to discontinuation of all LLT. CONCLUSION: Statin-related ADR was associated with an increased risk of subsequent CVD event, indicating that these patients should be monitored more closely. Continued lipid-lowering medication is of importance to protect against CVD events and mortality.
引用
- Insani WN, Whittlesea C, Ju C, et al. Statin-related adverse drug reactions in UK primary care consultations: A retrospective cohort study to evaluate the risk of cardiovascular events and all-cause mortality. Br J Clin Pharmacol. 2022. PMID: 35695656. doi:10.1111/bcp.15438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。